Bristol Myers Squibb annual gross margin
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bristol Myers Squibb Gross Margin Growth & History (BMY)
Bristol Myers Squibb's gross margin was 71.08% for fiscal 2025.
View full Bristol Myers Squibb company overviewBristol Myers Squibb annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 71.08% | +0.00 pp |
| 2024 | 2024-12-31 | 71.08% | −5.16 pp |
| 2023 | 2023-12-31 | 76.24% | −1.80 pp |
| 2022 | 2022-12-31 | 78.04% | −0.53 pp |
| 2021 | 2021-12-31 | 78.57% | +6.26 pp |
| 2020 | 2020-12-31 | 72.31% | +3.21 pp |
| 2019 | 2019-12-31 | 69.10% | −2.23 pp |
| 2018 | 2018-12-31 | 71.34% | +0.67 pp |
| 2017 | 2017-12-31 | 70.67% | −3.87 pp |
| 2016 | 2016-12-31 | 74.54% | −1.85 pp |
| 2015 | 2015-12-31 | 76.39% | +1.16 pp |
| 2014 | 2014-12-31 | 75.24% | +3.43 pp |
| 2013 | 2013-12-31 | 71.81% | −2.03 pp |
| 2012 | 2012-12-31 | 73.84% | +0.19 pp |
| 2011 | 2011-12-31 | 73.65% | +0.73 pp |
| 2010 | 2010-12-31 | 72.92% | +0.25 pp |
| 2009 | 2009-12-31 | 72.67% | +2.68 pp |
| 2008 | 2008-12-31 | 69.99% | +1.49 pp |
| 2007 | 2007-12-31 | 68.50% | — |
Bristol Myers Squibb quarterly gross margin
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 71.28% | −1.24 pp |
| Q1 2026 | 2026-03-31 | 70.22% | −2.70 pp |
| Q4 2025 | 2025-12-31 | 67.24% | +6.23 pp |
| Q3 2025 | 2025-09-30 | 71.89% | −3.24 pp |
| Q2 2025 | 2025-06-30 | 72.52% | −0.71 pp |
| Q1 2025 | 2025-03-31 | 72.92% | −2.37 pp |
| Q4 2024 | 2024-12-31 | 61.01% | −15.07 pp |
| Q3 2024 | 2024-09-30 | 75.13% | −2.01 pp |
| Q2 2024 | 2024-06-30 | 73.22% | −1.16 pp |
| Q1 2024 | 2024-03-31 | 75.29% | −2.08 pp |
| Q4 2023 | 2023-12-31 | 76.08% | −1.18 pp |
| Q3 2023 | 2023-09-30 | 77.15% | −1.88 pp |
| Q2 2023 | 2023-06-30 | 74.38% | −2.74 pp |
| Q1 2023 | 2023-03-31 | 77.37% | −1.42 pp |
| Q4 2022 | 2022-12-31 | 77.27% | −3.08 pp |
| Q3 2022 | 2022-09-30 | 79.02% | −1.27 pp |
| Q2 2022 | 2022-06-30 | 77.12% | −1.93 pp |
| Q1 2022 | 2022-03-31 | 78.79% | +4.44 pp |
| Q4 2021 | 2021-12-31 | 80.34% | +6.63 pp |
| Q3 2021 | 2021-09-30 | 80.29% | +4.03 pp |
| Q2 2021 | 2021-06-30 | 79.05% | +5.69 pp |
| Q1 2021 | 2021-03-31 | 74.34% | +8.31 pp |
| Q4 2020 | 2020-12-31 | 73.71% | +5.07 pp |
| Q3 2020 | 2020-09-30 | 76.26% | +6.06 pp |
| Q2 2020 | 2020-06-30 | 73.35% | +4.79 pp |
| Q1 2020 | 2020-03-31 | 66.03% | −3.16 pp |
| Q4 2019 | 2019-12-31 | 68.63% | −3.41 pp |
| Q3 2019 | 2019-09-30 | 70.20% | −1.19 pp |
| Q2 2019 | 2019-06-30 | 68.56% | −3.30 pp |
| Q1 2019 | 2019-03-31 | 69.19% | −0.69 pp |
| Q4 2018 | 2018-12-31 | 72.04% | +2.89 pp |
| Q3 2018 | 2018-09-30 | 71.39% | +1.45 pp |
| Q2 2018 | 2018-06-30 | 71.86% | +2.36 pp |
| Q1 2018 | 2018-03-31 | 69.88% | −4.45 pp |
| Q4 2017 | 2017-12-31 | 69.15% | −4.47 pp |
| Q3 2017 | 2017-09-30 | 69.95% | −3.54 pp |
| Q2 2017 | 2017-06-30 | 69.50% | −5.74 pp |
| Q1 2017 | 2017-03-31 | 74.34% | −1.71 pp |
| Q4 2016 | 2016-12-31 | 73.62% | −4.17 pp |
| Q3 2016 | 2016-09-30 | 73.49% | +0.45 pp |
| Q2 2016 | 2016-06-30 | 75.24% | −0.43 pp |
| Q1 2016 | 2016-03-31 | 76.04% | −3.00 pp |
| Q4 2015 | 2015-12-31 | 77.79% | +0.48 pp |
| Q3 2015 | 2015-09-30 | 73.04% | −1.28 pp |
| Q2 2015 | 2015-06-30 | 75.67% | +1.15 pp |
| Q1 2015 | 2015-03-31 | 79.04% | +4.44 pp |
| Q4 2014 | 2014-12-31 | 77.31% | +5.98 pp |
| Q3 2014 | 2014-09-30 | 74.32% | +3.22 pp |
| Q2 2014 | 2014-06-30 | 74.52% | +1.89 pp |
| Q1 2014 | 2014-03-31 | 74.60% | +2.35 pp |
| Q4 2013 | 2013-12-31 | 71.34% | −3.01 pp |
| Q3 2013 | 2013-09-30 | 71.09% | −2.49 pp |
| Q2 2013 | 2013-06-30 | 72.63% | +0.65 pp |
| Q1 2013 | 2013-03-31 | 72.25% | −2.93 pp |
| Q4 2012 | 2012-12-31 | 74.35% | −0.59 pp |
| Q3 2012 | 2012-09-30 | 73.58% | −0.09 pp |
| Q2 2012 | 2012-06-30 | 71.98% | −0.77 pp |
| Q1 2012 | 2012-03-31 | 75.19% | +1.99 pp |
| Q4 2011 | 2011-12-31 | 74.94% | +2.60 pp |
| Q3 2011 | 2011-09-30 | 73.68% | +0.35 pp |
| Q2 2011 | 2011-06-30 | 72.75% | −0.47 pp |
| Q1 2011 | 2011-03-31 | 73.20% | +0.37 pp |
| Q4 2010 | 2010-12-31 | 72.33% | +0.81 pp |
| Q3 2010 | 2010-09-30 | 73.32% | +0.83 pp |
| Q2 2010 | 2010-06-30 | 73.22% | −0.52 pp |
| Q1 2010 | 2010-03-31 | 72.83% | −0.21 pp |
| Q4 2009 | 2009-12-31 | 71.53% | — |
| Q3 2009 | 2009-09-30 | 72.49% | +3.59 pp |
| Q2 2009 | 2009-06-30 | 73.74% | +5.84 pp |
| Q1 2009 | 2009-03-31 | 73.04% | — |
| Q3 2008 | 2008-09-30 | 68.90% | — |
| Q2 2008 | 2008-06-30 | 67.90% | — |
Bristol Myers Squibb gross margin trends
Over the last five fiscal years, Bristol Myers Squibb's gross margin decreased from 72.31% to 71.08%, a change of −1.23 percentage points. The latest reported quarter, Q2 2026, shows 71.28%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bristol Myers Squibb source filings ↗Community posts
Bristol Myers reports deeper myeloma responses with iberdomide regimen
Bristol Myers Squibb ($BMY) presented Phase 3 EXCALIBER-RRMM results for iberdomide combined with daratumumab and dexamethasone in relapsed or refractory multiple myeloma. Among 420 evaluable patients, 41.1% achieved a complete response wit ...
Bristol Myers reports sustained two-year Sotyktu responses in psoriatic arthritis
Bristol Myers ($BMY) Squibb presented two-year follow-up from the POETYK PsA-2 extension study of Sotyktu in psoriatic arthritis. Among patients continuously receiving treatment, the ACR20 response rate was 76.2% using observed data and 65. ...
